Tocilizumab for the Treatment of Rheumatoid Arthritis and Other Systemic Autoimmune Diseases: Current Perspectives and Future Directions

Table 1

Phase III randomized controlled trials of tocilizumab for RA patients. Summary of the results of seven phase III randomized controlled trials of tocilizumab. DMARDs: disease modifying antirheumatic drugs, IR: inadequate response, TCZ: tocilizumab, anti-TNF: anti-tumor necrosis factor inhibitor, MTX: methotrexate.

Study	Reported year	Population	Week at evaluation	Treatment arms	Patient (𝑛)	Response rates (%)			Remission rate (%)	Radiological progression
						ACR20	ACR50	ACR70	DAS28<2.6	TSS: Total Sharp score	ES: Erosion score	JSNS: Joint space narrowing score
SAMURAI	2007	DMARDs IR	52 W	TCZ (8)	157	78	64	44	59	2.3	0.9	1.5
				DMARDs	145	34	13	6	3	6.1	3.2	2.9
TOWARD	2008	DMARDs IR	24 W	TCZ (8) + DMARDs	803	61	38	21	30
				DMARDs	413	25	9	3	3
RADIATE	2008	Anti-TNF IR	24 W	TCZ (4) + MTX	161	30	17	5	8
				TCZ (8) + MTX	170	50	29	12	30
				placebo + MTX	158	10	4	1	2
OPTION	2008	MTX IR	24 W	TCZ (4) + MTX	186	48	31	12	13
				TCZ (8) + MTX	191	59	44	22	27
				placebo + MTX	189	26	11	2	1
SATORI	2009	MTX IR	24 W	TCZ (8)	61	80	49	30	43
				MTX	64	25	11	6	2
AMBITION	2010	MTX,; anti-TNF naïve	24 W	TCZ (8)	286	70	44	28	34
				MTX	284	53	34	15	12
LITHE	2011	MTX IR	52 W	TCZ (4) + MTX	394	47	29	16	30	0.34	0.21	0.13
				TCZ (8) + MTX	398	56	30	20	47	0.29	0.17	0.12
				MTX	393	25	10	4	8	1.13	0.71	0.42